All In MedTech

Device Trial Radar · NCT07889375

RIGHTEST iFree 2 CGM System for Glycemic Control in Adults With Diabetes Mellitus

An Open-label, Multicenter, Randomized, Parallel-group Trial to Assess Glycemic Control With the RIGHTEST iFree 2 Continuous Glucose Monitoring System in Adults With Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

324

Planned (sponsor's estimate)

Start

May 15, 2026

Primary completion

Dec 31, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Bionime CorporationNot on our public-company list
Sponsor type
Industry
First posted
Oct 22, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to find out whether using a real-time continuous glucose monitoring (CGM) system can improve daily blood sugar control compared with usual self-monitoring of blood glucose (SMBG; finger-stick testing) in people with diabetes who are treated with insulin. This study will include adults with type 1 or type 2 diabetes who have less-than-ideal blood sugar control while using insulin. The main questions it aims to answer are: * Does CGM-guided diabetes management lead to a larger decrease in HbA1c from baseline to about 6 months than SMBG-guided management? * Does CGM use increase the time that glucose stays in the target range and reduce low blood sugar episodes, without causing new safety problems? Researchers will compare two groups. One group will use the RIGHTEST iFree 2 CGM system together with a smartphone app to view glucose data in real time. The other group will use standard finger-stick blood glucose monitoring with an approved blood glucose meter as their main tool for checking glucose. Both groups will continue to receive routine diabetes care from their usual health-care providers. Participants will take part in regular clinic visits over approximately 6 months. At these visits, study staff will review glucose records, adjust diabetes treatment if needed, and collect information such as HbA1c and other blood tests, device data, and questionnaires about quality of life and diabetes-related distress. Safety information and any device problems will also be recorded. The results will help determine whether CGM can be used as a routine tool to improve long-term blood sugar control in people with diabetes.

Conditions

  • Diabetes (DM)

Interventions

  • Continuous Glucose Monitoring (CGM)Device

    Participants assigned to this arm will use a continuous glucose monitoring (CGM) system as the main tool for day-to-day glucose management. The system consists of a disposable subcutaneous glucose sensor, a reusable transmitter, and the RIGHTEST iFree 2 smartphone application for real-time data display and alerts. Sensors are worn continuously and replaced according to the product labeling over the \~6-month study period. CGM data will be reviewed by participants and study clinicians to guide self-management and diabetes treatment adjustments in addition to usual care.

  • Self-monitoring of blood glucose (SMBG)Device

    Participants assigned to this arm will use self-monitoring of blood glucose (SMBG) with a capillary finger-stick blood glucose meter as their primary tool for day-to-day diabetes management. An approved meter (e.g., RIGHTEST Max Plus blood glucose meter) and test strips will be provided, together with training on correct use and recording of results. Participants will measure their blood glucose at a frequency consistent with routine diabetes care and the recommendations of their treating physician (for example before meals, at bedtime, and as clinically indicated). SMBG values and downloaded meter records will be reviewed at study visits to guide insulin and other diabetes treatment adjustments. No real-time continuous glucose monitoring data will be used in this arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in glycated hemoglobin (HbA1c) from baseline to Week 24Time frame: Baseline and 24 weeks after randomization (end of treatment period)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.